^
Association details:
| Biomarker: | BAP1 negative + BRCA1 mutation |
|---|---|
| Cancer: | Mesothelioma |
| Drug: | Rubraca (rucaparib) (PARP inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
MiST1: A phase IIa trial of rucaparib in patients harbouring BAP1/BRCA1 deficient relapsed malignant mesothelioma.
Published date:
05/13/2020
Excerpt:
MiST1 was a single centre, open label single arm phase IIa design with prospective molecular stratification; cytoplasmic/negative BAP1 or BRCA1 deficient MM was deemed eligible. Treatment was...rucaparib...Molecular eligibility was 89% for BAP1 alone, 50% BRCA1 alone, and 39% BAP1+BRCA1....MiST1 using the PARP inhibitor R met its primary endpoint of disease control rate at 12 weeks, showing promising efficacy with manageable toxicity.
DOI:
10.1200/JCO.2020.38.15_suppl.9057
Trial ID:
